How To Share Glp1 Progress Data With Your Doctor

Your provider can only help you if they know what is happening between appointments. This share GLP-1 progress data with doctor resource covers the essential information you need to make informed decisions. Learning how to share GLP-1 progress data with your doctor transforms a routine check-in into a productive conversation that leads to better outcomes. Instead of vague answers like "it's going okay," you can show concrete trends and patterns.

Key Takeaways: - Discover why your tracking data matters at appointments - Understand what data to include in your report - Learn how to organize your progress report - Questions to Ask at Each Visit - Digital vs. Paper: Choosing Your Format

This guide covers exactly what to bring, how to organize it, and how to make your appointments more efficient and effective.

Why Your Tracking Data Matters at Appointments

Most provider visits for GLP-1 medication last 10 to 20 minutes. That is not a lot of time. Without organized data, much of the appointment gets spent trying to recall details. When did the nausea start? How much weight did you lose last month? Are you hitting your protein targets?

Bringing structured data changes the dynamic entirely. Your provider can quickly scan your trends and focus on what matters. They can spot patterns you might have missed, like side effects that spike after dose increases or weight loss that slows when protein intake drops.

Available evidence indicates that patients who bring organized health data to appointments receive more personalized care. Providers can make better dose adjustment decisions when they see your complete history rather than a snapshot from a single weigh-in at the office.

Your data also creates continuity. If you see different providers or have a telehealth visit with someone new, your tracking history brings them up to speed immediately. This is especially important with who want to give you the best care possible.

What Data to Include in Your Report

Not every detail matters. Focus on the metrics that help your provider make decisions.

Essential data to share:

• Dose history. Every dose, the date, and any skipped injections. Include which injection site you used if you are rotating.
• Weight trend. Weekly weigh-ins shown as a trend line or list. Monthly averages are even more useful than individual readings.
• Side effects. When they occurred, severity (mild, moderate, severe), and how long they lasted. Note whether they appeared after a dose change.
• Medication adherence. Were you consistent with your weekly injection schedule? Any missed or late doses?

"What makes tirzepatide particularly interesting is the dual GIP/GLP-1 mechanism. We're seeing that GIP receptor activation appears to amplify the metabolic effects in ways we didn't fully anticipate from the preclinical data.") Dr. Ania Jastreboff, MD, PhD, Yale School of Medicine, lead author of SURMOUNT-1

Helpful additional data:

• Body measurements (waist, hips, etc.)
• Daily protein intake averages
• Exercise frequency and type
• Sleep quality notes
• Blood pressure readings if you monitor at home
• Non-scale victories

The can compile most of this data into a shareable report automatically.

---

Free Download: GLP-1 Progress Report Template A clean, provider-friendly template covering doses, side effects, weight, measurements, and questions for your doctor. Get yours free (we'll email it to you instantly.

[Download CTA Button]

---

How to Organize Your Progress Report

A wall of raw numbers is not helpful. Organize your data so your provider can scan it in under a minute.

Use this structure:

1. Summary at the top. One or two sentences covering the big picture. Example: "Lost 7 pounds this month. Nausea improved after week 2 on the new dose. Protein intake averaging 85g per day."

2. Dose timeline. A simple list showing each dose date, amount, and injection site. Flag any missed doses.

3. Weight chart or table. Weekly averages, ideally shown as a simple chart. If you use the , it generates this automatically.

4. Side effect log. Organized by date with severity ratings. Highlight anything new or worsening.

5. Questions for your provider. Write these down before the appointment. People forget their questions when they are in the room. Common questions include asking about dose adjustments, managing specific side effects, and timeline expectations.

Keep it to one or two pages. Your provider does not need a novel. They need a clear, scannable summary.

Questions to Ask at Each Visit

Having data is only half the equation. You also need to ask the right questions to get the most from your appointment.

During titration (dose increase phase): - Is my current dose working, or should we increase? - Are my side effects normal for this stage? - When should I expect to reach my target dose? - Should I adjust my eating habits as my appetite changes?

During maintenance: - How long should I stay on this dose? - What does a plan for eventual dose reduction look like? - Should I get lab work done to check my metabolic markers? - Are there lifestyle changes that could support my results?

If progress stalls: - Could anything besides the medication be affecting my results? - Should we adjust the dose or timing? - Are there additional tests that might reveal underlying issues? - Would adding exercise or adjusting my help?

Write your top 3 questions at the bottom of your progress report. This ensures you cover them even if the appointment feels rushed.

Digital vs. Paper: Choosing Your Format

Both formats work. The best choice depends on your provider's preferences and your own habits.

Digital options: - The generates a PDF report you can email or show on your phone - Screenshots of your tracking charts - A shared health portal if your provider's system supports uploads

Paper options: - A printed one-page summary using the FormBlends progress report template - A simple notebook with organized sections - Printed charts from your tracking app

Many telehealth providers prefer digital data because they can zoom in on specific charts during a video call. In-person providers often appreciate a printed page they can add to your file.

If you are a FormBlends member, your provider may already have access to some of your tracking data through the platform. Ask them what they can see and what additional information would be most helpful.

Frequently Asked Questions

How often should I share data with my provider?

Share a thorough report at every scheduled appointment. For most GLP-1 patients, this means every 4 to 8 weeks during the titration phase and every 2 to 3 months during maintenance. Contact your provider between visits if you experience concerning symptoms or a prolonged plateau.

What if my provider does not seem interested in my tracking data?

Some providers may not be accustomed to receiving detailed patient data. Start with a brief one-page summary. If your provider consistently does not engage with your data, consider whether a provider who values shared decision-making might be a better fit. are trained to review and use patient tracking data.

Should I share my data before or during the appointment?

If possible, send your report 24 to 48 hours before the appointment. This gives your provider time to review it and come prepared with specific recommendations. If that is not an option, bring it to the appointment and give them a minute to scan it before looking at questions.

What if I have not been tracking consistently?

Start from wherever you are. Even a few weeks of data is better than none. Note any gaps honestly in your report. Your provider understands that tracking is a skill that improves over time. The most important thing is to start and build the habit going forward.

Start your protocol Today

Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you, consultations are free and confidential.

---

Sources & References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
8. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
11. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
12. Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816

Nothing in this article should be construed as medical advice. The information provided is educational only. Always consult with your healthcare provider before beginning, modifying, or discontinuing any medication or treatment. FormBlends connects patients with licensed providers for individualized care.

Last updated: 2026-03-24